464 related articles for article (PubMed ID: 18661429)
21. Recent concepts in non-alcoholic fatty liver disease.
Adams LA; Angulo P
Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Alessi N; Cabibi D; Caldarella R; Licata A; Massenti F; Tarantino G; Marchesini G; Craxì A
Am J Gastroenterol; 2008 May; 103(5):1136-44. PubMed ID: 18477344
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
Kang H; Greenson JK; Omo JT; Chao C; Peterman D; Anderson L; Foess-Wood L; Sherbondy MA; Conjeevaram HS
Am J Gastroenterol; 2006 Oct; 101(10):2247-53. PubMed ID: 17032189
[TBL] [Abstract][Full Text] [Related]
24. The metabolic syndrome and nonalcoholic fatty liver disease.
Collantes RS; Ong JP; Younossi ZM
Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review.
Salt WB
J Insur Med; 2004; 36(1):27-41. PubMed ID: 15104027
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C and nonalcoholic fatty liver disease.
Ramesh S; Sanyal AJ
Semin Liver Dis; 2004 Nov; 24(4):399-413. PubMed ID: 15605308
[TBL] [Abstract][Full Text] [Related]
27. Pathology of nonalcoholic fatty liver disease.
Yeh MM; Brunt EM
Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease.
Leclercq I
Bull Mem Acad R Med Belg; 2010; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
[TBL] [Abstract][Full Text] [Related]
29. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
[TBL] [Abstract][Full Text] [Related]
30. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
31. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study.
Stepanova M; Rafiq N; Younossi ZM
Gut; 2010 Oct; 59(10):1410-5. PubMed ID: 20660697
[TBL] [Abstract][Full Text] [Related]
32. The evolving role of leptin and adiponectin in chronic liver diseases.
Tsochatzis E; Papatheodoridis GV; Archimandritis AJ
Am J Gastroenterol; 2006 Nov; 101(11):2629-40. PubMed ID: 16952281
[TBL] [Abstract][Full Text] [Related]
33. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.
Adinolfi LE; Durante-Mangoni E; Zampino R; Ruggiero G
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():52-5. PubMed ID: 16225474
[TBL] [Abstract][Full Text] [Related]
34. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases.
Powell EE; Jonsson JR; Clouston AD
Dig Dis; 2010; 28(1):186-91. PubMed ID: 20460909
[TBL] [Abstract][Full Text] [Related]
35. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
36. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
[TBL] [Abstract][Full Text] [Related]
37. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
38. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
39. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
Serfaty L; Lemoine M
Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C and steatosis.
Björnsson E; Angulo P
Arch Med Res; 2007 Aug; 38(6):621-7. PubMed ID: 17613353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
